Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab and Nivolumab with Azacitidine in AML
NCT04913922Phase 2Recruiting
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- May 2021
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of relatlimab in acute myeloid leukemia (AML), sponsored by Ludwig Maximilian University of Munich. Primary endpoint: Maximum Tolerated Dose at 12 months. Started May 2021; status: recruiting.
02
Drugs
relatlimab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04913922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913922.